Characteristics of Minimally Oversized Adeno-Associated Virus Vectors Encoding Human Factor VIII Generated Using Producer Cell Lines and Triple Transfection.
Several ongoing clinical studies are evaluating recombinant adeno-associated virus (rAAV) vectors as gene delivery vehicles for a variety of diseases. However, the production of vectors with genomes >4.7 kb is challenging, with vector preparations frequently containing truncated genomes. To determine whether the generation of oversized rAAVs can be improved using a producer cell-line (PCL) process, HeLaS3-cell lines harboring either a 5.1 or 5.4 kb rAAV vector genome encoding codon-optimized cDNA for human B-domain deleted Factor VIII (FVIII) were isolated. High-producing "masterwells" (MWs), defined as producing >50,000 vg/cell, were identified for each oversized vector. These MWs provided stable vector production for >20 passages. The quality and potency of the AAVrh8R/FVIII-5.1 and AAVrh8R/FVIII-5.4 vectors generated by the PCL method were then compared to those prepared via transient transfection (TXN). Southern and dot blot analyses demonstrated that both production methods resulted in packaging of heterogeneously sized genomes. However, the PCL-derived rAAV vector preparations contained some genomes >4.7 kb, whereas the majority of genomes generated by the TXN method were ≤4.7 kb. The PCL process reduced packaging of non-vector DNA for both the AAVrh8R/FVIII-5.1 and the AAVrh8R/FVIII-5.4 kb vector preparations. Furthermore, more DNA-containing viral particles were obtained for the AAVrh8R/FVIII-5.1 vector. In a mouse model of hemophilia A, animals administered a PCL-derived rAAV vector exhibited twofold higher plasma FVIII activity and increased levels of vector genomes in the liver than mice treated with vector produced via TXN did. Hence, the quality of oversized vectors prepared using the PCL method is greater than that of vectors generated using the TXN process, and importantly this improvement translates to enhanced performance in vivo.
Sanofi , Framingham, Massachusetts.
Bindu
B
Nambiar
Sanofi , Framingham, Massachusetts.
Cathleen
C
Cornell Sookdeo
Sanofi , Framingham, Massachusetts.
Patricia
P
Berthelette
Sanofi , Framingham, Massachusetts.
Robert
R
Jackson
Sanofi , Framingham, Massachusetts.
Susan
S
Piraino
Sanofi , Framingham, Massachusetts.
Brenda
B
Burnham
Sanofi , Framingham, Massachusetts.
Shelley
S
Nass
Sanofi , Framingham, Massachusetts.
David
D
Souza
Sanofi , Framingham, Massachusetts.
Catherine R
CR
O'Riordan
Sanofi , Framingham, Massachusetts.
Karen A
KA
Vincent
Sanofi , Framingham, Massachusetts.
Seng H
SH
Cheng
Sanofi , Framingham, Massachusetts.
Donna
D
Armentano
Sanofi , Framingham, Massachusetts.
Sirkka
S
Kyostio-Moore
D000818:Animals; D002460:Cell Line; D000229:Dependovirus / Q000235:genetics*; D005169:Factor VIII / Q000096:biosynthesis / Q000235:genetics*; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics* / Q000627:therapeutic use; D006367:HeLa Cells; D006467:Hemophilia A / Q000235:genetics / Q000628:therapy*; D006801:Humans; D051379:Mice; D014162:Transfection
D005169:Factor VIII
AAV vector production; AAVrh8R; FVIII; oversized genome; producer cell line